Currently, Cadrenal Therapeutics Inc’s (CVKD) stock is trading at $0.49, marking a fall of -3.92% from last night’s close. At this price, the stock is -84.39% below its 52-week high of $3.14 and 24.05% above its 52-week low of $0.40. Based on the past 30-day period, the stock price is -23.47% below the high and +4.00% above the low.
The 200-day Simple moving average is often placed more emphasis on by traders because of daily price changes. Investors will use the SMA-200 in different situations in trading activity as a key indicator to determine their support and resistance levels, and at the moment, CVKD’s SMA-200 is $0.7898.
CVKD’s price to book ratio for the most recent quarter was 0.83, resulting in an 0.93 price to cash per share for the period.
How does Cadrenal Therapeutics Inc (CVKD) stock rate among analysts? Buy, sell, or hold?
The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. Currently, there are 2 brokerage firms that recommend the stock as a Strong Buy. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1. Using a scale of 1-5, the current average recommendation is 5.00 in simple terms.
Cadrenal Therapeutics Inc (CVKD): Earnings History
If we examine Cadrenal Therapeutics Inc’s recent earnings history, in the last quarter ended on 12/30/2023, it posted adjusted earnings per share of -$0.05, slashing the consensus of -$0.08. In other words, it beat the consensus by $0.03, resulting in a 37.50% surprise. In the 3 months period before the previous quarter which was closed on 12/30/2023, the stock recorded adjusted earnings per share of -$0.05 in contrast with the Outlook of -$0.08. That was a difference of $0.03 and a surprise of 37.50%.
Cadrenal Therapeutics Inc (CVKD): Earnings History
Most analysts expect public companies to report earnings and revenue in line with their projections, but sometimes these figures vary from what they actually expected. In the current quarter, the company had earnings predictions made by 2 different analysts, who are expecting earnings to fall in between the range of -0.05 and -0.09 with an average Earnings Estimate of -0.07 which is in contrast with the last year earnings estimate of -0.41 and also replicates 82.93% growth rate year over year.
Cadrenal Therapeutics Inc (NASDAQ: CVKD) Ownership Details
I will give a breakdown of the key shareholders in Cadrenal Therapeutics Inc (CVKD). Recent figures show that the company’s insiders hold 47.04% of shares. A total of 7 institutional investors hold shares in the company, making 3.45% of its stock and 6.52% of its float.
Dec 30, 2023, it was reported that the Company’s largest institutional holder is Armistice Capital, LLC holding total of 0.41 million shares that make 2.59% of the company’s total number of shares and are currently priced at 0.2 million.
The securities firm Renaissance Technologies, LLC holds 79100.0 shares of CVKD, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 0.49%, and the holding percentage of shares is valued at 38846.0.
An overview of Cadrenal Therapeutics Inc’s technicals
In order to learn about trade movements and investor behavior, it is best to analyze the short, medium, and long term technical indicators along with the average volume of a stock. A 20-day average of the stock’s daily volume suggests Cadrenal Therapeutics Inc (CVKD) traded 255,721 shares per day, with a moving average of $0.5960 and price change of -0.1308. With the moving average of $0.8016 and a price change of -0.9700, about 390,049 shares changed hands on average over the past 50 days. Finally, CVKD’s 100-day average volume is 288,432 shares, alongside a moving average of $0.7219 and a price change of +0.1100.
